×
About 4,378 results

ALLMedicine™ Vitiligo Center

Research & Reviews  1,527 results

Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpre...
https://doi.org/10.1111/bjd.21671
The British Journal of Dermatology; Batchelor JM, Gran S et. al.

May 22nd, 2022 - Validated outcome measures are needed for vitiligo trials. Assess construct validity, interpretability, reliability and acceptability of the Vitiligo Noticeability Scale (VNS). We used images of vitiligo before and after treatment, plus outcome da...

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04927975

May 20th, 2022 - Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adve...

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

May 20th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
https://clinicaltrials.gov/ct2/show/NCT05247489

May 17th, 2022 - The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% b...

see more →

Guidelines  1 results

Guidelines for the management of vitiligo: the European Dermatology Forum consensus.
https://doi.org/10.1111/j.1365-2133.2012.11197.x
The British Journal of Dermatology; Taieb A, Alomar A et. al.

Aug 7th, 2012 - The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. T...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  72 results

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

May 20th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04927975

May 20th, 2022 - Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adve...

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
https://clinicaltrials.gov/ct2/show/NCT05247489

May 17th, 2022 - The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% b...

Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04822584

May 13th, 2022 - Treatment Strategy: Multicentric, parallel double blind randomized phase 2 prospective study comparing baricitinib (4mg/day) + narrowband UVB TL01 versus placebo + narrowband UVB TL01 Follow-up of the study: patients included in this study will st...

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04971200

Apr 20th, 2022 - Tildrakizumab is a monoclonal antibody against interleukin (IL) 23, specifically anti-IL23p19. It is approved in the USA, Europe and Australia for psoriasis. The psoriasis dose is 100mg administered subcutaneously at weeks 0, 4 and every 12 weeks....

see more →

News  138 results

JAK Inhibitor Therapies Continue to Show Promise in Patients With Vitiligo
https://www.medscape.com/viewarticle/971834

Apr 8th, 2022 - BOSTON — Patients with vitiligo treated with a topical formulation of the Janus kinase (JAK) inhibitor ruxolitinib had significant repigmentation after 1 year on the therapy, reported investigators from two randomized controlled trials presented a...

Vitiligo From Checkpoint Inhibitors Not Limited to Melanoma
https://www.medscape.com/viewarticle/968490

Feb 15th, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Vitiligo induced by immune checkpoint inhibitors (ICIs) can occur in virtually any type of cancer. Why This Matter...

Ruxolitinib Cream Meets Primary Endpoints in Phase 3 Vitiligo Trial
https://www.medscape.com/viewarticle/960220

Oct 4th, 2021 - A topical cream formulation of the JAK inhibitor ruxolitinib was superior to its vehicle for treating vitiligo across all primary and secondary endpoints in two multicenter phase 3 trials presented together at the annual meeting of the European Ac...

Insurance Coverage for Vitiligo Treatment Varies Widely in the US, Analysis Finds
https://www.medscape.com/viewarticle/956472

Aug 12th, 2021 - Health insurance coverage policies for vitiligo treatment lack uniformity and are marked by significant gaps in coverage, which may disproportionately affect patients of color. Those are the conclusions from an analysis of vitiligo treatment cover...

Pigmented Basal Cell Carcinoma With Annular Leukoderma
https://www.mdedge.com/dermatology/article/241961/nonmelanoma-skin-cancer/pigmented-basal-cell-carcinoma-annular-leukoderma
Marcus L. Elias, MD, Radhika Srivastava, MD et. al.

Jun 23rd, 2021 - To the Editor: Annular leukoderma, or the halo phenomenon, is a circular reaction of hypopigmentation that most commonly is observed alongside congenital nevi, acquired melanocytic nevi, blue nevi, Spitz nevi, vitiligo, and rarely melanoma. 1 There.

see more →

Patient Education  7 results see all →